Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks

Aung, Theingi; Halsey, Jim; Kromhout, Daan; Gerstein, Hertzel C.; Marchioli, Roberto; Tavazzi, Luigi; Geleijnse, Johanna M.; Rauch, Bernhard; Ness, Andy R; Galán, Pilar; Chew, Emily Y.; Bosch, Jackie; Collins, Rory; Lewington, Sarah; Armitage, Jane; Clarke, Robert

doi:10.1001/jamacardio.2017.5205

Cited by 574 publications

(370 citation statements)

References 30 publications

Supporting

Mentioning

332

Contrasting

Unclassified

Order By: Relevance

“…In the main results, omega-3 fatty acid supplementation had no significant association with CHD death (rate ratio [RR] 0.93; 99% CI 0.83 to 1.03), non-fatal MI (RR 0.97; 99% CI 0.87 to 1.08) or any CHD events (RR 0.96; 95% CI 0.90 to 1.01) 1. Omega-3 supplementation also had no significant association with major vascular events (RR 0.97; 95% CI, 0.93 to 1.01) overall or in any subgroups.…”

mentioning

confidence: 82%

“…A meta-analysis of large randomised trials has assessed the association of omega-3 fatty acid (eicosapentaenoic acid [EPA] and docosahexanoic acid [DHA]) supplement use with the risk of fatal and non-fatal cardiovascular heart disease (CHD) and major vascular events 1. The meta-analysis (10 trials; 77,917 high-risk people) included studies that involved at least 500 participants and ran for at least 1 year (mean duration 4.4 years) 1.…”

mentioning

confidence: 99%

“…The meta-analysis (10 trials; 77,917 high-risk people) included studies that involved at least 500 participants and ran for at least 1 year (mean duration 4.4 years) 1. The main outcomes included fatal CHD, non-fatal myocardial infarction (MI), stroke, major vascular events and all-cause mortality, as well as major vascular events in study population subgroups.…”

mentioning

confidence: 99%

“…Of the 77,917 participants, 61% were men and the mean age at entry was 64 years 1. About 66% of participants had a history of CHD, 28% had previously had a stroke and 37% had diabetes.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Omega-3 fatty acid supplements and cardiovascular disease

2018

DTB

View full text Add to dashboard Cite

mentioning

confidence: 82%

mentioning

confidence: 99%

mentioning

confidence: 99%

“…Of the 77,917 participants, 61% were men and the mean age at entry was 64 years 1. About 66% of participants had a history of CHD, 28% had previously had a stroke and 37% had diabetes.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Omega-3 fatty acid supplements and cardiovascular disease

2018

DTB

View full text Add to dashboard Cite

“…A recent meta-analysis demonstrated that omega-3 fatty acids had no significant association with fatal or nonfatal coronary heart disease or any major vascular events [29]; however, there are currently no published CVD outcome trials using these agents. Both the Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) and Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh CV Risk PatienTs with Hypertriglyceridemia (STRENGTH) are underway and will hopefully help determine this class’ position in diabetic dyslipidemia.…”

Section: Combination Therapiesmentioning

confidence: 99%

Towards more specific treatment for diabetic dyslipidemia

Rodríguez

Newman

Schwartzbard

2018

Current Opinion in Lipidology

View full text Add to dashboard Cite

Purpose of review Treatment of diabetic dyslipidemia is necessary because of its impact on cardiovascular disease, which is the leading cause of death in patients with diabetes. In the past, standard treatment of diabetic dyslipidemia focused only on correcting lipids. Although this remains the mainstay of treatment, because new antihyperglycemic treatments reduce cardiovascular events with minimal effect on dyslipidemia, a new approach is both timely and relevant. Recent findings LDL-lowering remains the focus of treatment for diabetic dyslipidemia, especially in patients with both diabetes and cardiovascular disease (CVD). Higher intensity statin therapy or lower LDL cholesterol goals are recommended in these patients. Combination therapy, especially with ezetimibe, fibrates, bile acid sequestrants, PCSK9 inhibitors and omega 3 fatty acids should be considered along with selected new agents to reduce glycemia. Summary As diabetic dyslipidemia plays a key role in CVD, aggressive treatment is indicated. New research targets include apo-CIII and lipoprotein(a) [Lp(a)]. In addition, new antihyperglycemic therapy is changing diabetes care and altering treatment guidelines. The most recent American Diabetes Association Standards of Care has expanded its recommendations for people with CVD and diabetes, suggesting that medications validated to improve cardiac health should be strongly considered.

show abstract

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk

Nicholls

Lincoff

Garcia

et al. 2020

JAMA

684

487

View full text Add to dashboard Cite

It remains uncertain whether the omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) reduce cardiovascular risk.OBJECTIVE To determine the effects on cardiovascular outcomes of a carboxylic acid formulation of EPA and DHA (omega-3 CA) with documented favorable effects on lipid and inflammatory markers in patients with atherogenic dyslipidemia and high cardiovascular risk.

show abstract

Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks

Cited by 574 publications

References 30 publications

Omega-3 fatty acid supplements and cardiovascular disease

Omega-3 fatty acid supplements and cardiovascular disease

Towards more specific treatment for diabetic dyslipidemia

Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk

Contact Info

Product

Resources

About